Escrich Víctor, Romero-Aranda Cristina, López Rosario, de Toro María, Metola Ángela, Ezcurra Begoña, Gómez-Orte Eva, Cabello Juan
Oncology Area, Center for Biomedical Research of La Rioja-CIBIR, 26006 Logrono, Spain.
Scientific Computing Group (GRUCACI), University of La Rioja, 26006 Logroño, Spain.
Cancers (Basel). 2024 Jun 26;16(13):2340. doi: 10.3390/cancers16132340.
The human Integrator complex is a set of 15 subunits that mediates processing of small nuclear RNAs (snRNAs), and which later participates in splicing messenger RNAs (mRNAs). In addition, it controls the pause and release of RNA polymerase II (RNA pol II) at specific gene promoters in response to growth factors. Mutations in Integrator-complex subunit 6 () are associated with different types of tumors. However, the gene product does not have a significant prognostic value as a biomarker for tumor progression. Here we show that Integrator-complex deregulation is involved in 8.3% of the colorectal cancer cases diagnosed from the population screen carried out in La Rioja (Spain) from the years 2017 to 2019. Lack of Integrator-complex function, measured by an increased level of unprocessed snRNA, is a prognostic biomarker and correlates with a poorer prognosis in colorectal-cancer patients. The transcriptomic profile of all analyzed colorectal tumors shows a strong alteration of the metabolic state of tumor cells, which compromises standard energy production through mitochondrial respiration, known as the Warburg effect. Furthermore, there is a significant upregulation of genes involved in extracellular matrix organization and collagen rearrangement. This is consistent with tissue reorganization in a growing tumor forming a polyp. Crossing the molecular data generated in this study with the follow-up of patients from population screening indicates that population screening combined with early typing of tumors appears to be the most efficient way to increase patient survival.
人类整合因子复合体是由15个亚基组成的集合体,介导小核RNA(snRNA)的加工,随后参与信使RNA(mRNA)的剪接。此外,它还能响应生长因子,控制RNA聚合酶II(RNA pol II)在特定基因启动子处的暂停和释放。整合因子复合体亚基6( )的突变与不同类型的肿瘤相关。然而, 基因产物作为肿瘤进展的生物标志物并没有显著的预后价值。在这里,我们表明,在2017年至2019年于西班牙拉里奥哈进行的人群筛查中诊断出的8.3%的结直肠癌病例中,存在整合因子复合体失调。通过未加工的snRNA水平升高来衡量的整合因子复合体功能缺失是一种预后生物标志物,并且与结直肠癌患者较差的预后相关。所有分析的结直肠癌肿瘤的转录组图谱显示肿瘤细胞的代谢状态发生了强烈改变,这损害了通过线粒体呼吸进行的标准能量产生,即所谓的瓦伯格效应。此外,参与细胞外基质组织和胶原重排的基因有显著上调。这与生长中的肿瘤形成息肉时的组织重组是一致的。将本研究中生成的分子数据与人群筛查患者的随访结果相结合表明,人群筛查结合肿瘤早期分型似乎是提高患者生存率的最有效方法。